Literature DB >> 16842953

[Prevalence of Acinetobacter baumannii and Pseudomonas aeruginosa isolates resistant to imipenem by production of metallo-beta-lactamase].

M Ait El Kadi1, M Aghrouch, M Seffar, J El harti, A Bouklouze, Y Cherrah, K Souly, M Zouhdi.   

Abstract

UNLABELLED: Metallo-beta-lactamases (MBL) are enzymes produced by Gram-negative bacilli such as Pseudomonas aeruginosa and Acinetobacter baumannii. These enzymes make these isolates resistant to imipenem. AIM: The aim of this study was to determine the prevalence of this resistance mechanism in Pseudomonas aeruginosa and Acinetobacter baumannii strains identified in the bacteriology laboratory of the Rabat Ibn Sina teaching hospital, Morocco. MATERIALS AND
METHOD: Screening for MBL was systematic in all resistant strains and/or strains with decreased sensitivity to imipenem, according to Dongeun Yong et al.'s method, using a sterilized solution of EDTA 0.5 M pH 8.
RESULTS: Eighty-five bacterial strains (48 P. aeruginosa and 37 A. baumannii) were identified 23% (11) and 57% (21) of which were respectively resistant to the imipenem. The prevalence of MbetaL producing strains was 27% for P. aeruginosa and 38% for A. baumannii.
CONCLUSION: These results show that the frequency of these strains is increases in our hospital and that their emergence represents a serious therapeutic and epidemiological problem. This means that we need to implement the supervision of hospital microbial environment and strictly apply hygiene measures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842953     DOI: 10.1016/j.medmal.2006.05.003

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  1 in total

1.  Intestinal carriage of antibiotic resistant Acinetobacter baumannii among newborns hospitalized in Moroccan neonatal intensive care unit.

Authors:  Btissam Arhoune; Bouchra Oumokhtar; Fouzia Hmami; Samira El Fakir; Kaoutar Moutaouakkil; Fouzia Chami; Abdelhak Bouharrou
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.